| DVLT |
Datavault AI Inc. |
92%
|
Reciprocal relationship from DVLT graph: department, 85 employees in our general and administrative department. None of our employees are represented by a labor union with respect to his or her emplo… |
| ORMP |
Oramed Pharmaceuticals Inc. |
92%
|
Reciprocal relationship from ORMP graph: Pursuant to the Warrant Agreement, the Company deferred its right to receive an amortization payment scheduled to be paid by Scilex on October 1, 2025 as set … |
| PHOENIX-ASIA-HOLDINGS-LIMITED |
PHOENIX-ASIA-HOLDINGS-LIMITED |
90%
|
Phoenix Asia agreed to purchase, 100% of the issued and outstanding shares of common stock of ACEA Pharma |
| AMERISOURCEBERGEN-CORPORATION |
AMERISOURCEBERGEN-CORPORATION |
85%
|
alth 110, LLC (“Cardinal Health 110”) and AmerisourceBergen Corporation (“AmerisourceBergen”). Distributors have agreements in place that provide us with access to large retail chains, including CVS,… |
| MCK |
McKesson Corporation |
85%
|
5, LLC (“Cardinal Health 105”), ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or withi… |
| MCK |
McKesson Corporation |
85%
|
Reciprocal relationship from MCK graph: Reciprocal relationship from SCLX graph: 5, LLC (“Cardinal Health 105”), ships them to temperature-controlled customer distribution centers, which are generall… |
| A |
Agilent Technologies, Inc. |
72%
|
ury strategy would be delayed, which could cause a material adverse effect on our business, prospects, and market price of our listed securities. If we are not able to enter into a custodial agreemen… |
| A |
Agilent Technologies, Inc. |
72%
|
Reciprocal relationship from A graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from A graph: Reciprocal relationship from SCLX graph: ury strategy would be delayed, which coul… |
| AARD |
Aardvark Therapeutics, Inc. |
72%
|
ement with EAR SPV LLC, a Delaware corporation (“EAR SPV”) and Vivasor Holding Company (“VHC”), a privately held biotechnology company, pursuant to which, among other things, EAR SPV agreed to sell, … |
| AARD |
Aardvark Therapeutics, Inc. |
72%
|
Reciprocal relationship from AARD graph: Reciprocal relationship from SCLX graph: ement with EAR SPV LLC, a Delaware corporation (“EAR SPV”) and Vivasor Holding Company (“VHC”), a privately held biot… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from BMY grap… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from SCLX graph: to promote GLOPERBA® for gout to … |
| COLL |
Collegium Pharmaceutical, Inc. |
72%
|
Reciprocal relationship from COLL graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from COLL graph: Reciprocal relationship from SCLX graph: alth 110, LLC (“Cardinal Health 110… |
| COLL |
Collegium Pharmaceutical, Inc. |
72%
|
alth 110, LLC (“Cardinal Health 110”) and AmerisourceBergen Corporation (“AmerisourceBergen”). Distributors have agreements in place that provide us with access to large retail chains, including CVS,… |
| SNYNF |
Sanofi |
72%
|
arket uptake. Prescription Lidocaine Patch Market Overview Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from SNYN… |
| ALLERGAN-INC-BRISTOL-MYERS-SQUIBB-COMPANY-TEVA-P |
ALLERGAN-INC-BRISTOL-MYERS-SQUIBB-COMPANY-TEVA-P |
62%
|
to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout… |
| BIODELIVERY-SCIENCES-INTERNATIONAL-INC |
BIODELIVERY-SCIENCES-INTERNATIONAL-INC |
62%
|
alth 110, LLC (“Cardinal Health 110”) and AmerisourceBergen Corporation (“AmerisourceBergen”). Distributors have agreements in place that provide us with access to large retail chains, including CVS,… |
| COMBIMATRIX-CORPORATION |
COMBIMATRIX-CORPORATION |
62%
|
ury strategy would be delayed, which could cause a material adverse effect on our business, prospects, and market price of our listed securities. If we are not able to enter into a custodial agreemen… |
| DECISION-RESOURCES-GROUP |
DECISION-RESOURCES-GROUP |
62%
|
arket uptake. Prescription Lidocaine Patch Market Overview Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief… |
| FORTIS-ADVISORS-LLC |
FORTIS-ADVISORS-LLC |
62%
|
o other available therapies. Health Technology Assessment (“HTA”) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, incl… |
| LABORATORIES-LIMITED |
LABORATORIES-LIMITED |
62%
|
alth 110, LLC (“Cardinal Health 110”) and AmerisourceBergen Corporation (“AmerisourceBergen”). Distributors have agreements in place that provide us with access to large retail chains, including CVS,… |
| NOVARTIS-PHARMACEUTICALS-CEPHALON-INC-ROCHE-AG-P |
NOVARTIS-PHARMACEUTICALS-CEPHALON-INC-ROCHE-AG-P |
62%
|
to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout… |
| PAR |
PAR Technology Corporation |
62%
|
Reciprocal relationship from PAR graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from PAR graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from PAR grap… |
| PAR-PHARMACEUTICAL-INC |
PAR-PHARMACEUTICAL-INC |
62%
|
nts with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. If the commercial supply of our commercial products, clinical suppl… |
| SEMNUR-MERGER-AGREEMENT-SIGMA-MERGER-SUB-INC |
SEMNUR-MERGER-AGREEMENT-SIGMA-MERGER-SUB-INC |
62%
|
o other available therapies. Health Technology Assessment (“HTA”) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, incl… |
| SEMNUR-SIGMA-MERGER-SUB-INC |
SEMNUR-SIGMA-MERGER-SUB-INC |
62%
|
o other available therapies. Health Technology Assessment (“HTA”) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, incl… |
| SORRENTO-THERAPEUTICS-INC |
SORRENTO-THERAPEUTICS-INC |
62%
|
ement with EAR SPV LLC, a Delaware corporation (“EAR SPV”) and Vivasor Holding Company (“VHC”), a privately held biotechnology company, pursuant to which, among other things, EAR SPV agreed to sell, … |
